5:30 PM
 | 
Mar 14, 2013
 |  BC Extra  |  Company News

Vanda withdraws Fanaptum MAA

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) withdrew an MAA for Fanaptum iloperidone to treat schizophrenia after EMA's CHMP requested data from the ongoing Phase III REPRIEVE trial. Vanda said the...

Read the full 127 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >